journal cover

Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics

Nov 14, 2019

Noha H SayedAhmed S Kamel

Get paper from

Abstract

Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's diseases. Vilda's effect is mostly linked to PI3K/Akt signaling in CNS. Moreover, PI3K/Akt activation rep...read more

Mentioned in this Paper

Alzheimer's Disease
Cognition
Enzyme Inhibitors
Glial Fibrillary Acidic Protein
Huntington Disease
Immunohistochemistry
Mitochondria
Nerve Degeneration
Neurotransmitters
Parkinson Disease
3
1
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Huntington Disease

Huntington disease is a hereditary neurodegenerative disease characterized by poor coordination and involuntary body movements. Discover the latest research on Huntington disease here.

Muscle Mitochondrial Networks

This feed focuses on the role of mitochondrial networks and energy metabolism in muscle cells. Discover the latest research here.

Cognitive Neuroscience

Cognitive neuroscience is the study of biological processes that underlie cognition and addresses the role of neural circuits in regulating cognitive activities. Here is the latest research.

LRRK2 Inhibitors

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease. Increased kinase activity of certain LRRK2 mutants is thought to underlie dopaminergic neuron damage. Thus, LRRK2 inhibitors offer the potential to target an underlying cause of the disease. Here is the latest research.

GLP-1 Signaling

GLP-1 signaling pathway has been well studied for its role in regulating glucose homeostasis, as well as its beneficial effects in energy and nutrient metabolism. Discover the latest research on this signaling pathway here.

Neuropeptides

There are >50 peptides released by neurons that function as neuromodulators, neurotransmitters, neurohormones, and hormones. Here is the latest research on the systemic function of neuropeptides in the body.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Triplet Repeat Disorders

Triplet Repeat Disorders are genetic disorders that occur as a result of expansion of trinucleotide repeats in certain genes. Examples include Huntington’s disease, certain types of spinocerebellar ataxia, and Fragile X syndrome, among others. Here is the latest research.

Parkinson's Disease

Parkinson's Disease is a progressive neurodegenerative disorder characterized by loss of muscle control, including trembling of the limbs and impaired balance. Here is the latest research.

Movement Disorders

Movement disorders are a group of nervous system disorders that increase or decrease voluntary or involuntary movements. Here is the latest research on genetic and environmental factors, as well as mechanisms that underlie movement disorders.

Neurotransmitters

Neurotransmitters are released from synaptic vesicles in presynaptic neurons in response to neural activity, diffuse across the synaptic cleft, and bind specific receptors in order to bring about changes in postsynaptic neurons. Here is the latest research.

© 2019 Meta ULC. All rights reserved

Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model

Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics

Nov 14, 2019

Noha H SayedAhmed S Kamel

PMID: 31728850

DOI: 10.1007/s13311-019-00805-5

Abstract

Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's diseases. Vilda's effect is mostly linked to PI3K/Akt signaling in CNS. Moreover, PI3K/Akt activation rep...read more

Mentioned in this Paper

Alzheimer's Disease
Cognition
Enzyme Inhibitors
Glial Fibrillary Acidic Protein
Huntington Disease
3
1

Similar Papers Found In These Feeds

Related Papers

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/vildagliptin-attenuates-huntingtons-disease/31728850